openPR Logo
Press release

Erectile Dysfunction Drugs Market 2017-2027 | Pfizer, Inc., Eli Lilly & Co., Bayer AG, Johnson & Johnson Services, Apricus Biosciences Inc., Dong-A Pharmaceutical Co. Ltd

01-25-2019 11:33 AM CET | Health & Medicine

Press release from: future market insights.

Erectile Dysfunction Drugs Market 2017-2027 | Pfizer, Inc., Eli

Erectile dysfunction also known as impotence is the state of sexual dysfunction where men cannot maintain erection during sexual intercourse. Erectile dysfunction mainly caused by chronic diseases like diabetes, cardiovascular diseases, neurological issues and hormonal insufficiency and drug side effects. Erectile dysfunction may develop due to lack penile blood supply, smoking, obesity, excessive alcohol intake and psychological problems. Erectile dysfunction can be addressed with wide range of interventions that include exercise, change in life style like smoking cessation and reduction in alcohol intake, pharmacotherapy, erection devices, penile implants, and drug injections into penis. Healthcare awareness regarding erectile dysfunction or sexual diseases has been a tremendous rise across the globe among both patient and healthcare professionals alike.

Erectile Dysfunction Drugs Market: Drivers and Restraints

Global erectile dysfunction drugs market is continue to witness positive growth owing to increased prevalence of chronic diseases, rising geriatric population substantiated with increase in prevalence of erectile dysfunction as age increases, increase in life style changes among young population would expected to fuel demand erectile dysfunction drugs over a period of forecast. The market erectile dysfunction drugs driven by increasing generic product launches by local players, possible patent expires of erectile dysfunction drugs in foreseeable future, and promising clinical development product pipeline expected to fuel the market for erectile dysfunction drugs over a period of forecast. However, side effects associated with use of erectile dysfunction drugs, availability of several counterfeit drugs, social taboo associated with erectile dysfunction in developing economies may hamper the growth of the erectile dysfunction drugs market over a period of forecast.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-3289

Erectile Dysfunction Drugs Market: Segmentation

Global erectile dysfunction drugs market has been segmented on the basis of product type, drug type, distribution channel and region.

Based on the product type, the global erectile dysfunction drugs market is segmented into the following:

Oral Medications

Topical Medications

Injections

Others

Based on the drug type, the global erectile dysfunction drugs market is segmented into the following:

Phosphodiestarse - 5 Inhibitors (PDE5I)

Avanafil

Sildenafil

Tadalafil

Vardenafil

Udenafil

Alprostadil

Testosterone

Others

Based on the distribution channel, the global erectile dysfunction drugs market is segmented into the following:

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Erectile Dysfunction Drugs Market: Overview

Global erectile dysfunction drugs market is oligopolistic in nature with few players dominant in the marketplace. Marketers in the erectile dysfunction drugs market is coming up with innovative marketing techniques to create the awareness among the stakeholders. Players in erectile dysfunction drugs markets developing newer therapies and formulations to gain larger market revenue share in the erectile dysfunction drugs market. Erectile dysfunction drugs market expected to decline in value terms over the forecast period owing expected patent losses over the forecast period. In erectile dysfunction drugs market, drugs segment like Phosphodiestarse - 5 Inhibitors (PDE5I) expected to witness significant growth over a period of forecast.

Erectile Dysfunction Drugs Market: Region-wise Outlook

Geographically, erectile dysfunction drugs market is segmented into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. North America and Europe will remain key markets for erectile dysfunction drugs market. Developed markets like North America and Europe is expected to witness robust growth owing to brand loyalty, presence of key players with differential offerings in the region. Moreover, key players in theerectile dysfunction drugs market are majorly focusing on both developed and developing regions markets to tap the increased market demand for erectile dysfunction drugs. Asia Pacific is anticipated to register positive growth owing to favourable patient demographics, increasing awareness regarding sexual diseases, and availability of affordable generic alternatives in the region.

Request to View TOC @ https://www.futuremarketinsights.com/toc/rep-gb-3289

Erectile Dysfunction Drugs Market: Key Players

Some players in erectile dysfunction drugs market include Pfizer, Inc., Eli Lilly & Co., Bayer AG, Johnson & Johnson Services, Apricus Biosciences Inc., Dong-A Pharmaceutical Co. Ltd, to name a few.

Future Market Insights is the premier provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in London, the global financial capital, and has delivery centers in the U.S. and India.
FMI’s research and consulting services help businesses around the globe navigate the challenges in a rapidly evolving marketplace with confidence and clarity. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. We continuously track emerging trends and events in a broad range of end industries to ensure our clients prepare for the evolving needs of their consumers.

U.S. Office, 616 Corporate Way, Suite 2-9018,, Valley Cottage, NY 10989,, United States, T: +1-347-9
616 Corporate Way, Suite 2-9018,

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Erectile Dysfunction Drugs Market 2017-2027 | Pfizer, Inc., Eli Lilly & Co., Bayer AG, Johnson & Johnson Services, Apricus Biosciences Inc., Dong-A Pharmaceutical Co. Ltd here

News-ID: 1533464 • Views:

More Releases from future market insights.

Facial Implants Market 2018 - 2028 | Key Players Include Implatech Associates Inc., Medical, KLS Martin Group
Facial Implants Market 2018 - 2028 | Key Players Include Implatech Associates In …
Facial implants are a type of medical device used to correct the facial structure or to provide more defined facial features including cheeks or chin & jawline. Facial Implants products are used for cosmetic reasons & are also used in medical crises such as accidents and injuries. Facial implants are also designed for augmentative or reconstructive surgeries. Facial implants give long lasting and permanent results that are a key factor
Pericarditis Treatment Market 2018 - 2028 | Pfizer Inc., Bayer AG, PerkinElmer Inc., ALLERGAN
Pericarditis Treatment Market 2018 - 2028 | Pfizer Inc., Bayer AG, PerkinElmer I …
Global Pericarditis Treatment: Market Insights  Pericarditis is a cardiovascular disease which represents the swelling of the pericardium wall of the heart. The main cause of pericardium disease is the inflammation of pericardium wall which is generally caused by viral infection. Other causes of pericarditis disease are renal failure, bacterial infections and intake of some drugs such as procainamide. Some of the common symptoms of pericarditis disease are shortness of breath, fatigue, rapid
Aldosteronism Treatment Market Drivers and Restraints | 2018 - 2028 Key Players are Pfizer Inc., Allergan plc., GE Healthcare
Aldosteronism Treatment Market Drivers and Restraints | 2018 - 2028 Key Players …
Aldosteronism is a type of hormonal disorder that occurs due to an imbalance in aldosterone and further leads to high blood pressure. In Aldosteronism, aldosterone is produced in excess by the adrenal gland that exceeds the normal body requirement. This causes the sodium levels to increase and lowers the potassium levels in the body. High levels of sodium in the blood lead to a high volume of blood and ultimately
Contouring Implants Market 2018 - 2028 | Key Players are ALPHA-HEALTH (ASIA) PTE Ltd., Stryker
Contouring Implants Market 2018 - 2028 | Key Players are ALPHA-HEALTH (ASIA) PTE …
Body Contouring refers to the medical-surgical procedure that alternates the shape of parts of the body via the removal of fat or skin. Body contouring implants procedures includes reshaping and resizing certain areas so the persons overall appearance is more balanced and in proportion. Body contouring implants are foreign materials that is made and molded prior to the person’s surgery and then inserted into the appropriate site. The body contouring

All 5 Releases


More Releases for Erectile

Global Erectile Dysfunction Devices Market Report
As per GME studies, on the Global Erectile Dysfunction Devices Market, it is analyzed that the market will grow at a CAGR of 6.5%. Erectile dysfunction incidence increases with growing age, about 5-10% of men under 40 years are the possible suspects for the dysfunctionality. This is projected to drive the ED device market in the coming years also. Raising the aforementioned disease prevalence and the growing percentage of tobacco
50 Open Clinical Studies Presently, To Treat Erectile Dysfunction To Boost The E …
Erectile dysfunction is known as the medical condition of penis, a recurrent inability of a man to reach and/or to maintain a penile erection sufficient for/during sexual activities. It is most probably an age-related factor, progressive condition, affecting some level of disorder (mild, moderate or severe) in about 50% of men aged 40-70 years, and with the increase in the age, severity of erectile dysfunction also increase with a ratio
Erectile Dysfunction Drugs Market Size, Erectile Dysfunction Drugsmarket Share, …
According to a new study published by Polaris Market Research the global erectile dysfunction drugs market is anticipated to reach USD 2.63 billion by 2025. Request for Sample of This Research Report @ https://bit.ly/2NXzatD Top Key Players:- Bayer AG Pfizer Eli Lilly & Co. Vivus, Inc. S.K. Chemicals Co. Ltd. Dong-A Pharmaceutical Co. Ltd Meda Pharmaceuticals Apricus Biosciences Make an inquiry before buying this report @ https://www.polarismarketresearch.com/industry-analysis/erectile-dysfunction-drugs-market/inquire-before-buying According to a new study published by Polaris Market Research the global erectile dysfunction
Erectile Dysfunction Market Industry Forecast till 2024
Erectile dysfunction is known as the medical condition of penis, a recurrent inability of a man to reach and/or to maintain a penile erection sufficient for/during sexual activities. It is most probably an age-related factor, progressive condition, affecting some level of disorder (mild, moderate or severe) in about 50% of men aged 40-70 years, and with the increase in the age, severity of erectile dysfunction also increase with a
Erectile Dysfunction: A Prominent Age Related Disorder
Erectile dysfunction is known as the medical condition of penis, a recurrent inability of a man to reach and/or to maintain a penile erection sufficient for/during sexual activities. It is most probably an age-related factor, progressive condition, affecting some level of disorder (mild, moderate or severe) in about 50% of men aged 40-70 years, and with the increase in the age, severity of erectile dysfunction also increase with a
Erectile Dysfunction - Pipeline Review, H2 2017
Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “Erectile Dysfunction - Pipeline Review, H2 2017”. Erectile dysfunction, or ED, is the inability of a man to have an erection hard enough to have sexual intercourse. It can also be known as impotence. Request For Sample Report@ http://www.marketresearchhub.com/enquiry.php?type=S&repid=1246564 The predisposing factors include tobacco usage, overweight, injuries, drug and alcohol use and medications, including antidepressants,